In May 2026, Argenx reported its First Quarter 2026 Financial Results and Business Update, and the FDA approved a label expansion for one of its autoimmune disease treatments. In July 2026, the company provided its Half Year and Second Quarter 2026 Financial Results and Business Update, and news emerged of its plan to acquire Forte Biosciences for $2.2 billion. August 2026 saw Argenx announce positive results from a Phase 3 study of Efgartigimod (ALKIVIA Study), which led to an increase in its share price. In September 2026, the company presented at the Wells Fargo 21st Annual Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. October 2026 brought a sharp decline in Argenx shares after the company discontinued a Phase 3 study of Vyvgart in Sjogren's disease due to futility, though this was somewhat mitigated by positive Phase 2 topline data for FB102 in celiac disease reported concurrently. Later that month, Argenx reported Third Quarter 2026 Financial Results with product net sales of $1.7 billion, a 54% year-over-year increase, partly attributed to a 'halo effect' from the seronegative myasthenia gravis launch, and mentioned a new confirmatory Phase 3 requirement in dermatomyositis. In November 2026, Argenx announced positive Phase 3 ALKIVIA study results for VYVGART Hytrulo in autoimmune myositis (immune-mediated necrotizing myopathy and dermatomyositis), with plans to submit a Supplemental Biologics License Application with the FDA for IMNM by the end of 2026.